The MDM2-p53 antagonist brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study
Open accessPublished version of a preprint
The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Brigimadlin (BI 907828) is an oral MDM2–p53 antagonist that has shown encouraging antitumor activity in vivo. We present phase Ia results from an open-label, first-in-human, phase Ia/Ib study investigating brigimadlin in patients with advanced solid tumors (NCT03449381). Fifty-four patients received escalating doses of brigimadlin on day 1 of 21-day cycles (D1q3w) or days 1 and 8 of 28-day cycles (D1D8q4w). Based on dose-limiting toxicities during cycle 1, the maximum tolerated dose was selected as 60 mg for D1q3w and 45 mg for D1D8q4w. The most common treatment-related adverse events (TRAE) were nausea (74.1%) and vomiting (51.9%); the most common grade ≥3 TRAEs were thrombocytopenia (25.9%) and neutropenia (24.1%). As evidence of target engagement, time- and dose-dependent increases in growth differentiation factor 15 levels were seen. Preliminary efficacy was encouraging (11.1% overall response and 74.1% disease control rates), particularly in patients with well-differentiated or dedifferentiated liposarcoma (100% and 75% disease control rates, respectively). Significance: We report phase Ia data indicating that the oral MDM2–p53 antagonist brigimadlin has a manageable safety profile and shows encouraging signs of efficacy in patients with solid tumors, particularly those with MDM2-amplified advanced/metastatic well-differentiated or dedifferentiated liposarcoma. Further clinical investigation of brigimadlin is ongoing. See related commentary by Italiano, p. 1765. This article is highlighted in the In This Issue feature, p. 1749
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, brigimadlin has a long half-life (30-60 h in human; 10 h in mice), which supports intermittent dose schedules,11”
From Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts (2026) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a first-in-human phase 1 clinical trial, brigimadlin displayed a favorable pharmacokinetic (PK) profile, with a long plasma elimination half-life and a low apparent volume of distribution.11”
From Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts (2026) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brodowicz, T., Broto, J. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy096 · Cited by 1,614
Gronchi, A., Miah, A. B., Dei Tos, A. P., Abecassis, N., Bajpai, J., Bauer, S., Biagini, R., Bielack, S., Blay, J. Y., Bolle, S., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.07.006 · Cited by 1,115
The MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches
Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 661
Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571
Gamboa, A. C., Gronchi, A., & Cardona, K. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21605 · Cited by 524
Critical aspects of the Bayesian approach to phase I cancer trials
Neuenschwander, B., Branson, M., & Gsponer, T. (2008) · Statistics in Medicine · doi:10.1002/sim.3230 · Cited by 439
Differential sensitivity of liposarcoma subtypes to chemotherapy
Jones, R. L., Fisher, C., Al-Muderis, O., & Judson, I. R. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.07.023 · Cited by 354
Well-differentiated liposarcoma and dedifferentiated liposarcoma: An updated review
Thway, K. (2019) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2019.02.006 · Cited by 332
Tisato, V., Voltan, R., Gonelli, A., Secchiero, P., & Zauli, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0500-5 · Cited by 256
Research works printed but not linked: 1
- Rudolph D, Gollner A, Blake S, Rinnenthal J, Wernitznig A, Weyer-Czernilofsky U,. BI 907828: a novel, potent MDM2 inhibitor that is suitable for high-dose intermittent schedules [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14–18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4868.
Cited by
Translating p53-based therapies for cancer into the clinic
Peuget, S., Zhou, X., & Selivanova, G. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-023-00658-3 · Cited by 190
The roles of E3 ubiquitin ligases in cancer progression and targeted therapy
Sampson, C., Wang, Q., Otkur, W., Zhao, H., Lu, Y., Liu, X., & Piao, H. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1204 · Cited by 182
MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
Wang, W., Albadari, N. G., Du, Y., Fowler, J. F., Sang, H. T., Xian, W., McKeon, F., Li, W., Zhou, J., & Zhang, R. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001026 · Cited by 173
Cholangiocarcinoma 2026: status quo, unmet needs and priorities
Bañales, J. M., Rodrigues, P. M., Affò, S., Andersen, J. B., Aspichueta, P., Boulter, L., Bridgewater, J. A., Calvisi, D. F., Cárdenas, A., Cardinale, V., et al. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01153-w · Cited by 138
p53/MDM2 signaling pathway in aging, senescence and tumorigenesis
Huang, Y., Che, X., Wang, P. W., & Qu, X. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.05.001 · Cited by 94
A first-in-human phase I study of a novel MDM2/p53 inhibitor alrizomadlin in advanced solid tumors
Zhang, X., Wen, X., Peng, R., Pan, Q., Weng, D., Ma, Y., Zhang, Y., Yang, J., Men, L., Wang, H., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103636 · Cited by 41
Thirasastr, P., & Somaiah, N. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221081073 · Cited by 30
p53 biology and reactivation for improved therapy in MDS and AML
Zawacka‐Pankau, J. (2024) · Biomarker Research · doi:10.1186/s40364-024-00579-9 · Cited by 28
Strategies for p53 Activation and Targeted Inhibitors of the p53-Mdm2/MdmX Interaction
Huang, Y., Wang, L., Zhou, Y., Bai, J., Li, N., Su, Z., & Cheng, X. (2025) · Cells · doi:10.3390/cells14080583 · Cited by 27
Ubiquitination in cancer: mechanisms and therapeutic opportunities
Zhu, S., Zhang, X., Liu, W., Zhou, Z. G., Xiong, S., Li, J., Chen, X., & Peng, C. (2025) · 癌症:英文版 · doi:10.1002/cac2.70044 · Cited by 28
Self-citationLu, L., Jifu, C., Xia, J., & Wang, J. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116753 · Cited by 27
Hong, Z., Liu, F., & Zhang, Z. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00552-0 · Cited by 25
Yoo, C., Lamarca, Á., Choi, H. J., Vogel, A., Pishvaian, M. J., Goyal, L., Ueno, M., Märten, A., Teufel, M., Geng, L., et al. (2024) · Future Oncology · doi:10.2217/fon-2023-0963 · Cited by 24
Self-citationGujarathi, R., Peshin, S., Zhang, X., Bachini, M., Meeks, M. N., Shroff, R. T., & Pillai, A. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000743 · Cited by 25
Novel Therapeutics in Soft Tissue Sarcoma
Mavroeidis, L., Napolitano, A., Huang, P. H., & Jones, R. L. (2024) · Cancers · doi:10.3390/cancers17010010 · Cited by 23
Harnessing p53 for targeted cancer therapy: new advances and future directions
Andrysík, Z., & Espinosa, J. M. (2025) · Transcription · doi:10.1080/21541264.2025.2452711 · Cited by 22
Huang, Y., Gao, Y., Lin, Z., & Miao, H. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101240 · Cited by 21
Watkins, J. A., Trotman, J., Tadross, J. A., Harrington, J., Hatcher, H. M., Horan, G., Prewett, S., Wong, H. H., McDonald, S., Tarpey, P. S., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02721-8 · Cited by 21
Current insights and future directions of Li-Fraumeni syndrome
Hosseini, M. (2024) · Discover Oncology · doi:10.1007/s12672-024-01435-w · Cited by 20
Lessons learned from 20 years of preclinical testing in pediatric cancers
Smith, M. A., Houghton, P. J., Lock, R. B., Maris, J. M., Gorlick, R. G., Kurmasheva, R. T., Li, X., Teicher, B. A., Chuang, J. H., Cruz, F. S. D., et al. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108742 · Cited by 20
Yamamoto, N., Tolcher, A. W., Hafez, N., Lugowska, I. A., Ramlau, R., Macarulla, T. M., Geng, J., Li, J., Teufel, M., Märten, A., et al. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s440979 · Cited by 19
Self-citationWang, Z., Zhang, X., Luo, Y., Song, Y., Xiang, C., He, Y., Wang, K., Yu, Y., Wang, Z., Peng, W., et al. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06751-1 · Cited by 19
Cui, X., Huang, T., Jiang, T., & Wang, H. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217540 · Cited by 19
Gollner, A., Rudolph, D., Weyer-Czernilofsky, U., Baumgartinger, R., Jung, P., Weinstabl, H., Ramharter, J., Grempler, R., Quant, J., Rinnenthal, J., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0783 · Cited by 18
The role of molecular testing in pancreatic cancer
Zhen, D. B., Safyan, R. A., Konick, E. Q., Nguyen, R., Pritchard, C. C., & Chiorean, E. G. (2023) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848231171456 · Cited by 18
MDM2 in Tumor Biology and Cancer Therapy: A Review of Current Clinical Trials
Russano, F., Sturlese, M., Dall’Olmo, L., Callegarin, F., Brugnolo, D., Fiore, P. D., Patti, V., Purpura, A. H.-S., Moro, S., Rastrelli, M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010099 · Cited by 17
Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection
Lesovaya, E. A., Fetisov, T. I., Bokhyan, B. Y., Павловна, М. В., Kulikov, E. P., Belitsky, G. A., Игоревич, К. К., & Геннадиевна, Я. М. (2024) · Cancers · doi:10.3390/cancers16020271 · Cited by 17
An update patent review of MDM2–p53 interaction inhibitors (2019–2023)
Twarda‐Clapa, A. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2419836 · Cited by 17
Molecularly Targeted Therapies in Oncology: Mechanisms, Resistance, and Combination Strategies
Giercuszkiewicz-Haśnik, K., MORAK-MŁODAWSKA, B. I., & Jeleń, M. (2026) · Molecules · doi:10.3390/molecules31071195 · Cited by 15
Molecular characteristics and systemic treatment options of liposarcoma: A systematic review
Zhou, X.-P., Xing, J., Sun, L.-B., Tian, S.-Q., Luo, R., Liu, W., Song, X.-Y., & Gao, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117204 · Cited by 15
MDM2 inhibition is associated with the emergence of TP53-altered clonal hematopoiesis
Khanna, V., Eslami, G., Reyes, R., Diep, R. T., Fernandez‐Pol, S., Stehr, H., Suarez, C. J., Pinto, H. A., Ford, J. M., Zhang, T. Y., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00823-x · Cited by 15
The Immune–Genomics of Cholangiocarcinoma: A Biological Footprint to Develop Novel Immunotherapies
Cammarota, A., Balsano, R., Pressiani, T., Bozzarelli, S., Rimassa, L., & Lleò, A. (2025) · Cancers · doi:10.3390/cancers17020272 · Cited by 14
Extrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and Outcome
Preston, W. A., Drill, E. N., Boerner, T., Gelfer, R., Harding, J. J., O'Reilly, E. M., Cercek, A., Abou‐Alfa, G. K., Park, W., Balachandran, V. P., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00206 · Cited by 14
Park, C., Kim, R., Bae, J. M., Lee, T., Song, S. Y., Kwak, Y., Kb, L., Youk, J., Keam, B., Kim, T. M., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2024.104097 · Cited by 13
Tosoni, B., Naghshineh, E., Zanin, I., Gallina, I., Pietro, L. D., Cleris, L., Nadai, M., Lecchi, M., Verderio, P., Pratesi, P., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf085 · Cited by 13
Lavernia, J., Claramunt, R., Romero, I., López‐Guerrero, J. A., Llombart-Bosch, A., & Machado, I. (2024) · Cancers · doi:10.3390/cancers16020432 · Cited by 13
Challenges and hope: latest research trends in the clinical treatment and prognosis of liposarcoma
Liu, H., Wang, X., Wang, X., Qiu, F., & Zhou, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1529755 · Cited by 14
Targeting p53 activation: Recent therapeutic advances in cancer and diabetic macular edema
Wang, Z., Zhang, S., Mélita, I. L., & Zhao, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117909 · Cited by 12
Extended molecular profiling in mesenchymal tumors: a consensus paper from the Italian Sarcoma Group
D’Ambrosio, L., Sbaraglia, M., Merlini, A., Rabino, M., Grignani, G., Appolloni, V., Badalamenti, G., Baldi, G. G., Bellan, E., Benelli, M., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104960 · Cited by 12
A metabolic crosstalk between liposarcoma and muscle sustains tumor growth
Manteaux, G., Amsel, A., Riquier-Morcant, B., Romero, J. P., Gayte, L., Fourneaux, B., Larroque, M., Gruel, N., Quignot, C., Pérot, G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51827-3 · Cited by 10
MDM2 inhibitors in sarcomas: results and next steps
Tortorelli, I., Napolitano, A., Zhou, Y., Huang, P. H., & Jones, R. L. (2025) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001146 · Cited by 8
Kim, M., Shim, H. S., Kim, S., Lee, I. H., Kim, J., Yoon, S., Kim, H., Park, I., Jeong, J. H., Yoo, C., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.1043 · Cited by 8
Sun, Q., Sun, R., He, B., Meng, H., Jin, J., & He, J. (2025) · Drug Development Research · doi:10.1002/ddr.70097 · Cited by 8
Progress in histology specific treatments in soft tissue sarcoma
Redaelli, S., Merlini, A., Khan, M. U., & Gronchi, A. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2384584 · Cited by 8
Targeting MDM2 in Soft-Tissue Sarcomas (and Other Solid Tumors): The Revival?
Italiano, A. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0605 · Cited by 8
Kim, M., Shim, H. S., Kim, S., Lee, I. H., Kim, J., Yoon, S., Kim, H., Park, I., Jeong, J. H., Yoo, C., et al. (2024) · Journal of Pathology and Translational Medicine · doi:10.4132/jptm.2023.11.01 · Cited by 6
Shroff, R. T., & Bachini, M. (2024) · Future Oncology · doi:10.1080/14796694.2024.2340959 · Cited by 7
Targeting liposarcoma: unveiling molecular pathways and therapeutic opportunities
Liu, H., Wang, X., Liu, L., Yan, B., Qiu, F., & Zhou, B. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1484027 · Cited by 7
Wang, W., Alley, A., Sun, N., Tadesse, M., Wang, X., & Zhang, R. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1663766 · Cited by 7
Elkrief, A., Odintsov, I., Smith, R. S., Vojnic, M., Hayashi, T., Khodos, I., Markov, V., Liu, Z., Lui, A. J. W., Bloom, J. L., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00241 · Cited by 6
Novel pharmacotherapies for the treatment of liposarcoma: a comprehensive update
Lee, T. Y., & von Mehren, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2427333 · Cited by 6
Courville, J., Barber, A., & Fura, A. (2025) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.70002 · Cited by 6
Schöffski, P., Sanfilippo, R. G., Martín‐Broto, J., Kawai, A., Desai, J., LoRusso, P. M., Maki, R. G., Jones, R. L., Blay, J., Smrke, A., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-0509 · Cited by 6
Self-citationTumor-Agnostic Therapy—The Final Step Forward in the Cure for Human Neoplasms?
El-Sayed, M. M., Bianco, J. R., Li, Y., & Fábián, Z. (2024) · Cells · doi:10.3390/cells13121071 · Cited by 6
Pikul, J., Machnicki, M. M., Rzepakowska, A., Winiarska, N., Chudy, A., Moskowicz, A., Król, K., Fus, Ł., Kostrzewa, G., & Stokłosa, T. (2025) · BMC Cancer · doi:10.1186/s12885-024-13421-0 · Cited by 6
Sekita, T., Asano, N., Kubo, T., Totsuka, H., Mitani, S., Hattori, N., Yoshida, A., Kobayashi, E., Komiyama, M., Ushijima, T., et al. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101074 · Cited by 5
Is it a new era for intrahepatic cholangiocarcinoma?
Liguori, C., Cacciaguerra, A. B., Giampieri, R., Mocchegiani, F., Sciortino, C., Vivarelli, M., Niger, M., Berardi, R., & Parisi, A. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104923 · Cited by 5
Kim, D., Sim, N. S., Woo, S., Kim, M. H., Lee, C., Hong, S. S., Kim, S. H., Hwang, H. K., Kang, C. M., Lee, W. J., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.1019 · Cited by 5
Choosing the right animal model for sarcoma research
Remiszewski, P., Siedlecki, E., Wełniak-Kamińska, M., Mikula, M., & Czarnecka, A. M. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-06013-z · Cited by 5
Zhang, Y., Wang, Z., Shi, X., Gao, C., Chen, A. L., Zhan, J., & Cai, B. (2026) · ACS Sensors · doi:10.1021/acssensors.5c02332 · Cited by 5
Twenty‐five years without progress: The enduring challenge of soft tissue sarcomas
Hardy, N. J., Frej, K. B. H., Nkansah, R., Olino, K. L., Deshpande, H. A., Ma, X., Trent, J. C., & Costa, P. A. (2025) · Cancer · doi:10.1002/cncr.35906 · Cited by 4
Targeted therapies in advanced biliary malignancies: a clinical review
Grewal, U. S., Gaddam, S. J., Beg, M. S., & Brown, T. J. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2387612 · Cited by 4
Heesen, P., Feusi, D., Vogel, B., Studer, G., Fuchs, B., & on behalf of the Swiss Sarcoma Network (2025) · Cancers · doi:10.3390/cancers17182944 · Cited by 3
Ye, P., Su, T., Wang, K., Yu, D., Chao, M., Fan, L., Wu, G., Wang, G., Gao, F., & Hua, L. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.174160 · Cited by 3
Suehara, Y., Kitada, R., Kamio, S., Ogura, K., Iwata, S., Kobayashi, E., Kawai, A., & Khosaka, S. (2024) · Journal of Orthopaedic Science · doi:10.1016/j.jos.2024.10.016 · Cited by 3
Establishing biomarkers for soft tissue sarcomas
Czarnecka, A. M., Chmiel, P., Błoński, P. J., & Rutkowski, P. L. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2346187 · Cited by 3
New targeted therapies in liposarcoma: state of art and future perspectives
Franza, A., Fabbroni, C., Pasquali, S., Casali, P. G., & Sanfilippo, R. G. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001055 · Cited by 3
Efficacy analysis of targeted P53 therapy in solid tumors
Wang, P., & Wang, F. (2025) · Medical Oncology · doi:10.1007/s12032-025-02930-y · Cited by 2
Li, H., Wang, S., Zhao, G., Li, J., Li, X., Wang, B., Zhang, Y., Yao, M., Guo, L., Ying, J., et al. (2026) · Interdisciplinary medicine · doi:10.1002/inmd.70087 · Cited by 2
Self-citationJalving, T., Dufau, C., Nieto, J. S., Altimari, D. M. D., Veen, S. E. V. H.-V., Jin, E. H.-M., Visser, N. L., van Boven, H. H., van der Graaf, W. T. A., van Houdt, W. J., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-1858 · Cited by 2
Precision Oncology in Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors
Fontebasso, A. M., Rytlewski, J. D., Blay, J., Gladdy, R. A., & Wilky, B. A. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2026.05.028 · Cited by 2
Surgical resection of a giant retroperitoneal dedifferentiated liposarcoma: a case report
Zhong, S., Yang, W., Li, Z., Li, R., & Fu, B. (2025) · Frontiers in Surgery · doi:10.3389/fsurg.2025.1650969 · Cited by 2
Curylova, L., Zambo, I. S., Neradil, J., Kýr, M., Jurackova, N., Pavlová, Š., Polášková, K., Múdrý, P., Štěrba, J., Veselská, R., et al. (2024) · Cellular Oncology · doi:10.1007/s13402-024-01020-x · Cited by 1
Ferroptosis as a therapeutic vulnerability in MDM2 inhibition in dedifferentiated liposarcoma
Yen, C., Chen, P., Chen, S., Wu, W., Yen, C., Lin, Y., Wu, P., Chen, C.-M., Wang, J., Chao, T., et al. (2025) · Oncology Letters · doi:10.3892/ol.2025.15015 · Cited by 1
Clinical diagnosis and treatment for well-differentiated liposarcoma: A clinical practice guideline
Cai, Y., Fang, Y., Zhao, G., Wang, Y., Ding, J., Wang, S., & Li, N. (2026) · The Innovation · doi:10.1016/j.xinn.2025.101249 · Cited by 1
Katsuya, Y., Koyama, T., Sato, J., Okada, M., & Yamamoto, N. (2026) · ESMO Real World Data and Digital Oncology · doi:10.1016/j.esmorw.2026.100692 · Cited by 1
Self-citationLamarca, Á., Ross, P. J., Wasan, H. S., Hubner, R. A., McNamara, M. G., Lopes, A., Palmer, D. H., Valle, J. W., & Bridgewater, J. A. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101833 · Cited by 1
Shulman, D. S., Vo, K. T., Balis, F. M., Lindsay, H., DeNardo, B. D., Place, A. E., Chi, S. N., Kamihara, J., O'neill, A. F., Church, A. J., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-0625 · Cited by 1
Brightline-1: When a Negative Trial Reveals Two Active Therapies
Shahnam, A., & Gounder, M. M. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-2134 · Cited by 1
Self-citationFirst person profile: Patricia M. LoRusso, DO
Nierengarten, M. B. (2023) · Cancer · doi:10.1002/cncr.35121 · Cited by 1
Ohki, R., Itahana, K., & Iwakuma, T. (2024) · Genes to Cells · doi:10.1111/gtc.13114 · Cited by 1
Aptullahoğlu, E. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10834-3 · Cited by 1
Vaubel, R. A., Zhang, W., Karbhari, N., Oh, J.-H., Waller, K. L., Mladek, A., Jain, S., Burgenske, D. M., Decker, P. A., Kosel, M. L., et al. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf259
Mahmasani, L. A., Harding, J. J., & Abou‐Alfa, G. K. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.01.005
Advances in Immunooncology and Precision Medicine in Cholangiocarcinoma
Brown, T. J., & Karasic, T. B. (2024) · Digestive Disease Interventions · doi:10.1055/s-0044-1787013
NEW CHEMICAL ENTITIES ENTERING PHASE III TRIALS IN 2023
Lin, D. W., Armstrong, M., Jiang, J. B., del Pozo, J., & Teijaro, C. N. (2024) · Medicinal chemistry reviews · doi:10.1021/mc-2024-vol59.ch18
Gallas, L. F., Pacca, A. M., & Natal, R. D. A. (2024) · Surgical and Experimental Pathology · doi:10.1186/s42047-024-00168-y
Neldemo, I., Gausi, K., Sarr, C., Friberg, L. E., Sailer, R., Lahmar, M. M., Jayadeva, G., Pérez‐Pitarch, A., Schmid, U., & Busse, D. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70031
Self-citationGupta, K., & Grimison, P. (2025) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.14168
Jonczak, E., Trent, J. C., Roland, C. L., & Haddad, E. N. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2025.04.010
Guevara, D. E., Assaad, M. A., Manohar, J., Sigouros, M., Otilano, J. R., King, A. S., Fedorov, C., Butusova, A., Aghajanyan, A., Channov, V., et al. (2025) · Academia oncology. · doi:10.20935/acadonco7774
Jo, U., Song, M. J., Jeong, J.-S., Song, H., & Song, J. S. (2025) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000001275
Aptullahoğlu, E. (2025) · Black Sea Journal of Engineering and Science · doi:10.34248/bsengineering.1696059
Liang, H., Wen, M., Liang, X., Lv, Z., & Fan, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1665723
Kamel, E. M., Khadrawy, S. M., Ali, M. A. M., Ahmed, N. A., Yassin, N. Y. S., Alkhedhairi, S., Alkhayl, F. F. A., & Lamsabhi, A. M. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117951
Navigating the p53‐MDM2 Landscape: Molecular Insights and Therapeutic Strategies
Mansour, M. A., Hassan, G. S., & Abouzid, K. A. M. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70264
Dod, T., Rathod, V., Surwade, P., Jadhao, T., Doifode, P., Tayade, R., Mhaske, S., & Tekale, G. (2026) · Journal of Pharmacognosy and Phytochemistry · doi:10.22271/phyto.2026.v15.i3d.15914
Zhuang, A., Zhou, X., Chengfei, X., Chen, Y., Wang, X., Li, R., Hu, J., Cheng, Y., Wan, Y., Wu, T., et al. (2026) · Cancer and Metastasis Reviews · doi:10.1007/s10555-026-10363-w
The crosstalk between p53 and selected signaling pathways in human diseases
Hashemi, N., Fazilat, A., Fathlou, Y., Moghadam, F. M., Hemmati-Dinarvand, M., & Valilo, M. (2026) · Discover Oncology · doi:10.1007/s12672-026-05742-2
Therapeutic targets in dedifferentiated liposarcoma
Pasquali, S. (2026) · Open Research Online (The Open University) · doi:10.21954/ou.ro.00111879
Metadata
- Authors
- LoRusso, P., Yamamoto, N., Patel, M. R., Laurie, S. A., Bauer, T. M., Geng, J., Davenport, T., Teufel, M., Li, J., Lahmar, M., & Gounder, M. M.
- Affiliations
- Yale Cancer Center (US)
- National Cancer Centre Japan (JP)
- Florida Cancer Specialists & Research Institute (US)
- Ottawa Hospital (CA)
- Sarah Cannon (US)
- Boehringer Ingelheim (United States) (US)
- Boehringer Ingelheim (Germany) (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Gounder, Mrinal M.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2023-06-03
- Volume
- 13
- Issue
- 8
- Pages
- 1802-1813
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC10401071
- OpenAlex
- W4379259102
- Cited by
- 101
- References
- 29
- Citations by year
- 2026: 21 · 2025: 35 · 2024: 41 · 2023: 4
- FWCI
- 12.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Discovery (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Boehringer Ingelheim (n/a)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Keywords
- brigimadlin, BI 907828, MDM2-p53 antagonist, p53, advanced solid tumors, metastatic solid tumors, liposarcoma, dedifferentiated liposarcoma, dose-limiting toxicity, maximum tolerated dose, growth differentiation factor 15, target engagement, oral anticancer drugs, treatment efficacy and safety
- MeSH terms
- Antineoplastic Agents, Heterocyclic Compounds, 4 or More Rings, Humans, Liposarcoma, Nausea, Neoplasms, Spiro Compounds, Tumor Suppressor Protein p53, Neoplasms, Second Primary, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.